The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report

Abstract

Background: The potential role of bevacizumab in the treatment of ovarian granulosa-cell tumors has not been evaluated.

Case: An 82 year old woman with refractory ovarian granulosa-cell carcinoma was treated with bevacizumab with symptomatic relief of ascites.

Conclusion: Bevacizumab may have a role in the management of malignant ascites in the patient with refractory granulosa-cell carcinoma of the ovary which should be confirmed in a larger series of well selected patients.

Conflict of interest statement

statement The authors have no conflicts of interest to declare.

Figures

Fig. 1

The ovarian granulosa-cell tumor cells expressed VEGF protein in a strong and diffuse pattern. The positivity was cytoplasmic. (×40).